Results 51 to 60 of about 7,162 (211)
British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva +5 more
wiley +1 more source
, 2023 Introduction Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) often caused by alternative complement dysregulation.
Halimi, Jean-Michel +9 more
core +1 more source
International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova +2 more
wiley +1 more source
Atypical Hemolytic Uremic Syndrome following Acute Type A Aortic Dissection
Case Reports in Hematology, 2020 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)-related disease that manifests as a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) and is caused by uncontrolled activation of ...
Eigo Ikushima +7 more
doaj +1 more source
NAD+‒circadian rhythm coupling in dementia
Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang +7 more
wiley +1 more source
, 2010 Atypical haemolytic uraemic syndrome (aHUS) is associated with a poor prognosis with regard to survival at presentation, recovery of renal function and transplantation.
Sam Machin +8 more
core +1 more source
Luminescence, Volume 41, Issue 5, May 2026.Solid‐state synthesis of nitrogen‐doped carbon quantum dots (CQDs) from hazelnut shell enables tunable structure and enhanced photoluminescence via metal‐ion engineering. Ba2+‐assisted CQDs exhibit improved graphitization and superior OLED efficiency, demonstrating a sustainable route for high‐performance optoelectronic materials.
Fatmanur Uyumaz Cengiz +6 more
wiley +1 more source
Xenotransplantation, Volume 33, Issue 3, May/June 2026.ABSTRACT Complement activation is a major barrier to xenotransplantation. We report detailed complement monitoring in a 58‐year‐old man who received a 10 gene–edited porcine heart expressing human complement regulators CD46 and CD55. Despite these transgenes and prophylactic systemic complement inhibition with C1 esterase inhibitor (C1INH), early ...
Michael A. Cole +25 more
wiley +1 more source
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. [PDF]
, 2014 Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of
Bresin, Elena +46 more
core +1 more source
Atypical hemolytic-uremic syndrome as one of the causes of acute kidney injury in pregnant women
Терапевтический архив, 2018 Obstetric atypical hemolytic uremic syndrome (aHUS) is one of the reasons for the development of acute kidney injury (AKI) and can determine the prognosis of both mother and child. Aim.
N L Kozlovskaya +3 more
doaj +1 more source